Skip to main content
SpringerLink
Log in

Management of patients receiving radionuclide therapy with unsealed radionuclides: a proposed approach to the definition of release criteria in Italy

  • Regular Article
  • Published:
The European Physical Journal Plus Aims and scope Submit manuscript

A Correction to this article was published on 18 November 2021

This article has been updated

Abstract

The decision to release a patient receiving medical treatments with unsealed radionuclides should take many factors into account, and is the balance among different requirements. The Italian legislative implementation of the new European Commission Basic Safety Standards (BSS) resulted in the recent Legislative Decree 101/2020, which sets specific dose constraints for the public and for carers and comforters. The aim of the present research is to assess acceptable release criteria (in terms of personal dose-equivalent rate at the moment of hospital discharge) to ensure compliance with the current regulatory framework in Italy. The MicroShield® code was used to derive a more realistic model for the emission of radioactivity by patients treated with radiopharmaceuticals. A geometric source-dependent correction factor, G(r), is introduced in order to take into account the volumetric distribution of the radionuclide into the human body and the attenuation of radiation from body tissues. The proposed approach has the potential to be routinely applied by clinic decision-makers to assess release criteria in the nuclear medicine practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Change history

References

  1. C.D. Kaur, K.K Mishra, A. Sahu, R. Panik, P. Kashyap, S.P. Mishra, A. Kumar, Theranostics: New Era in Nuclear Medicine and Radiopharmaceuticals, Medical Isotopes, Syed Ali Raza Naqvi and Muhammad Babar Imrani, IntechOpen. https://doi.org/10.5772/intechopen.91868. Available from: https://www.intechopen.com/books/medical-isotopes/theranostics-new-era-in-nuclear-medicine-and-radiopharmaceuticals

  2. G. Sgouros, L. Bodei, M. McDevitt, J. Nedrow, Author Correction: Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat. Rev. Drug Discov. 19(11), 819–819 (2020). https://doi.org/10.1038/s41573-020-0085-5

    Article  Google Scholar 

  3. International Atomic Energy Agency, Trends in Radiopharmaceuticals (ISTR-2019), Proceedings of an International Symposium, Vienna, Austria, 28 October–1 November 2019

  4. ICRP, Release of patients after therapy with unsealed radionuclides. ICRP Publication 94. (ICRP, 2004)

  5. European Commission, Radiation Protection Following Iodine-131 Therapy (Exposures Due to Out-Patients or Discharged In-Patients), Radiation Protection 97 (European Commission, Luxembourg, 1998)

  6. International Atomic Energy Agency, Release of patients after radionuclide therapy, Safety Reports Series No. 63. (IAEA, Vienna 2009)

  7. H. Zhang, L. Jiao, S. Cui, L. Wang, J. Tan, G. Zhang, Y. He, S. Ruan, S. Fan, W. Zhang, The study of external dose rate and retained body activity of patients receiving 131I therapy for differentiated thyroid carcinoma, Int J Environ Res Public Health. 11(10), 10991–11003 (2014)

  8. European Council Directive 2013/59/Euratom on basic safety standards for protection against the dangers arising from exposure to ionising radiation and repealing Directives 89/618/Euratom, 90/641/Euratom, 96/29/Euratom, 97/43/Euratom and 2003/122/Euratom. OJ of the EU. L13; 57: 1–73 (2014)

  9. Legislative Decree 31 July 2020 No. 101 implementing Directive 2013/59/Euratom – “Attuazione della direttiva 2013/59/Euratom, che stabilisce norme fondamentali di sicurezza relative alla protezione contro i pericoli derivanti dall–esposizione alle radiazioni ionizzanti, e che abroga le direttive 89/618/Euratom, 90/641/Euratom, 96/29/Euratom, 97/43/Euratom e 2003/122/Euratom e riordino della normativa di settore in attuazione dell–articolo 20, comma 1, lettera a), della legge 4 ottobre 2019, n. 117– . G.U. n. 201 del 12/08/2020, Supplemento ordinario n. 29/L

  10. M. Singleton, C. Griffiths, G. Morrison, T. Soanes, Dose constraints for comforters and carers, RR155 (HSE, 2003)

  11. International Atomic Energy Agency, International Basic Safety Standards for protection against ionizing radiation and for the safety of radiation sources, Safety Series No. 115 (IAEA, Vienna, 1996)

  12. D.S. Smith, M.G. Stabin, Exposure rate constants and lead shielding values for over 1,100 radionuclides. Health Phys. 102(3), 271–291 (2012). https://doi.org/10.1097/hp.0b013e318235153a

  13. NCRP report n. 155 (Bethesda, 2006)

  14. US Nuclear Regulatory Commission, NUREG-1556, Volume 9. Rev. 3 (2019)

  15. L.R. Coover, E.B. Silberstein, P.J. Kuhn, M.W. Graves, J. Nucl. Med. 41, 11 (2000)

    Google Scholar 

  16. US Nuclear Regulatory Commission, Regulatory Guide 8.39 (1997)

  17. MicroShield code, Grove Software, radiationsoftware.com (2012)

  18. ICRP OIR Data Viewer for Pub. 134, Pub. 137 and Pub. 141 v4010419, 2019 July 30

  19. D. Levart, E. Kalogianni, B. Corcoran et al., Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours. EJNMMI Phys. 6, 7 (2019). https://doi.org/10.1186/s40658-019-0243-1

    Article  Google Scholar 

  20. P.J. Calais, J.H. Turner, Radiation safety of outpatient 177Lu-octreotate radiopeptide therapy of neuroendocrine tumors. Ann. Nucl. Med. 28, 531–9 (2014)

    Article  Google Scholar 

  21. C. Olmstead, K. Cruz, R. Stodilka, P. Zabel, R. Wolfson, Quantifying public radiation exposure related to lutetium-177 octreotate therapy for the development of a safe outpatient treatment protocol. Nucl. Med. Commun. 36, 129–34 (2015)

    Article  Google Scholar 

  22. G.M. Contessa, S.A. De Crescenzo, P. Rossi, The application of the optimization principle in the Italian and European context. Radioprotection 56(3), 199–204 (2021). https://doi.org/10.1051/radiopro/2021019

Download references

Author information

Authors and Affiliations

  1. Medical Physics Section, ASL Roma 6, Borgo Garibaldi, 12, 00041, Rome, Italy

    Marco D’Arienzo

  2. ENEA, Italian National Agency for New Technologies, Energy and Sustainable Economic Development, Lungotevere Thaon di Revel 76, 00196, Rome, Italy

    Gian Marco Contessa & Sandro Sandri

  3. Fondazione Policlinico Universitario A. Gemelli IRCSS, L. go Agostino Gemelli, 8, 00168, Rome, Italy

    Luca Indovina

Authors
  1. Marco D’Arienzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gian Marco Contessa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sandro Sandri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Luca Indovina
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marco D’Arienzo.

Additional information

The original online version of this article was revised due to a wrong affiliation for the authors Gian Marco Contessa and Sandro Sandri.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

D’Arienzo, M., Contessa, G.M., Sandri, S. et al. Management of patients receiving radionuclide therapy with unsealed radionuclides: a proposed approach to the definition of release criteria in Italy. Eur. Phys. J. Plus 136, 1055 (2021). https://doi.org/10.1140/epjp/s13360-021-01735-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1140/epjp/s13360-021-01735-y

Search

Navigation